In a letter to the editor that appeared in The New York Times, senior lecturer Jonathan Byrnes advocates for a continuous flow of vaccinations to quickly protect the population against Covid-19. “We need two things: 1) a core of highly experienced supply chain managers supplementing the public health professionals; and 2) a management structure, probably under the Defense Production Act, to coordinate, organize and manage the supply chain,” Byrnes writes.
Writing for The Boston Globe, Prof. Ramesh Raskar underscores the importance of ensuring that every American has the opportunity to receive the Covid-19 vaccine without cost or without giving up their privacy. “By effectively communicating the privacy benefits of decentralized data collection and anonymized data reporting, mobile apps might diminish barriers to vaccination that exist due to privacy concerns,” writes Raskar.
Fast Company reporter Adele Peters spotlights Particles for Humanity, an MIT spinoff that is developing a new technology that makes it possible to deliver multiple doses of a vaccine in one shot. “The new technology works like traditional drug delivery,” writes Peters, “but with the addition of tiny time-release capsules filled with antigens, the part of the vaccine that stimulates the immune system so that it can later respond to a virus.”
On this episode of Freakonomics, Prof. Andrew Lo discusses the economics of drug development. “It’s important that we get the pricing of these vaccines correct so that they provide both a reasonable rate of return to investors who have risked their capital to develop these vaccines, while at the same time making sure that there’s no price gouging going on and that ultimately we provide access to everybody,” says Lo.
Writing for The New Yorker, Bernard Avishai spotlights Prof. Andrew Lo’s work exploring the need for a revolution in financial engineering to help spur the development of vaccines, and how a vaccine megafund could have assisted in bringing the Covid-19 pandemic under control. “The more I studied this, the more I realized that finance actually plays a huge role in drug development,” says Lo, “in many cases, way too big a role.”
Writing for The Washington Post, Prof. Robin Wolfe Scheffler underscores the importance of not only pursuing coronavirus vaccine development initiatives, but also “addressing the social and political factors that exacerbate disease and limit the access of many Americans to basic medical care.”
STAT reporter Kate Sheridan writes about MIT startup SQZ Biotech, which is developing a “technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell.”
The Broad Institute of MIT and Harvard is developing a Drug Repurposing Hub, which looks to “acquire samples of every drug ever developed to see if they can be used to treat diseases besides those for which they were intended,” writes Jonathan Saltzman for The Boston Globe.
Graduate student Maimuna Majumder writes for NPR about her research examining what caused an outbreak of the mumps in Arkansas in 2016. Majumder writes that her research shows, “why herd immunity is so important. When we vaccinate, we protect not only ourselves but the most vulnerable members of our communities, too.”
MIT researchers have developed a programmable vaccine that could be used to respond to disease outbreaks, reports Ben Gruber for Reuters. The vaccine harnesses “messenger RNA, a genetic material that can be programmed to fight any viral, bacterial or parasitic disease by provoking an amplified immune response.”
Karen Kaplan of The Los Angeles Times writes that MIT researchers have calculated that the measles vaccination rate among individuals exposed to the disease during the current outbreak ranges from 50 to 86 percent. “Vaccination rates in many of the communities that have been affected by this outbreak fall well below the necessary threshold to sustain herd immunity,” the researchers explain.
Based on the rapid spread of the measles outbreak, researchers believe that vaccination rates could be as low as 50 percent in some areas, Lisa Rapaport reports for Reuters. That rate “is far below the level necessary to achieve herd immunity,” explains graduate student Maimuna Majumder.
Joseph Flaherty of Wired writes about “Flowers,” a print created by postdoctoral fellow Tal Danino and MIT visiting artist Vik Muniz to educate people about the importance of vaccinations. Danino hopes to be able to apply the technique developed for creating the print, which contains real cancer and virus cells, to control the behaviors of specific cells and bacteria.
David Pogue of the PBS show NOVA examines Professor Paula Hammond’s work developing a new type of vaccine that delivers a DNA patch via tiny microscopic needles. Using DNA as the vaccine is a “very unique but also very powerful” approach, Hammond explains.